343 related articles for article (PubMed ID: 24083419)
41. Ruxolitinib: a review of its use in patients with myelofibrosis.
Plosker GL
Drugs; 2015 Feb; 75(3):297-308. PubMed ID: 25601187
[TBL] [Abstract][Full Text] [Related]
42. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
[TBL] [Abstract][Full Text] [Related]
43. Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
Lancman G; Mascarenhas J
Expert Rev Hematol; 2017 Jan; 10(1):23-28. PubMed ID: 27882812
[TBL] [Abstract][Full Text] [Related]
44. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
Mesa RA; Gotlib J; Gupta V; Catalano JV; Deininger MW; Shields AL; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Hare T; Erickson-Viitanen S; Sun W; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
J Clin Oncol; 2013 Apr; 31(10):1285-92. PubMed ID: 23423753
[TBL] [Abstract][Full Text] [Related]
45. Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition.
Komrokji R; Verstovsek S
Expert Rev Hematol; 2012 Dec; 5(6):631-41. PubMed ID: 23216593
[TBL] [Abstract][Full Text] [Related]
46. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
Cervantes F; Vannucchi AM; Kiladjian JJ; Al-Ali HK; Sirulnik A; Stalbovskaya V; McQuitty M; Hunter DS; Levy RS; Passamonti F; Barbui T; Barosi G; Harrison CN; Knoops L; Gisslinger H;
Blood; 2013 Dec; 122(25):4047-53. PubMed ID: 24174625
[TBL] [Abstract][Full Text] [Related]
47. Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib.
Saha C; Harrison C
Expert Rev Hematol; 2022 Jul; 15(7):583-595. PubMed ID: 35787092
[TBL] [Abstract][Full Text] [Related]
48. Managing side effects of JAK inhibitors for myelofibrosis in clinical practice.
Saeed I; McLornan D; Harrison CN
Expert Rev Hematol; 2017 Jul; 10(7):617-625. PubMed ID: 28571503
[TBL] [Abstract][Full Text] [Related]
49. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Verstovsek S; Kantarjian HM; Estrov Z; Cortes JE; Thomas DA; Kadia T; Pierce S; Jabbour E; Borthakur G; Rumi E; Pungolino E; Morra E; Caramazza D; Cazzola M; Passamonti F
Blood; 2012 Aug; 120(6):1202-9. PubMed ID: 22718840
[TBL] [Abstract][Full Text] [Related]
50. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy.
Harrison CN; Mesa RA; Kiladjian JJ; Al-Ali HK; Gisslinger H; Knoops L; Squier M; Sirulnik A; Mendelson E; Zhou X; Copley-Merriman C; Hunter DS; Levy RS; Cervantes F; Passamonti F; Barbui T; Barosi G; Vannucchi AM
Br J Haematol; 2013 Jul; 162(2):229-39. PubMed ID: 23672349
[TBL] [Abstract][Full Text] [Related]
51. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Sun W; Sandor V; Kantarjian HM
Haematologica; 2013 Dec; 98(12):1865-71. PubMed ID: 24038026
[TBL] [Abstract][Full Text] [Related]
52. Practical management of myelofibrosis with ruxolitinib.
Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
[TBL] [Abstract][Full Text] [Related]
53. Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.
Wade R; Rose M; Neilson AR; Stirk L; Rodriguez-Lopez R; Bowen D; Craig D; Woolacott N
Pharmacoeconomics; 2013 Oct; 31(10):841-52. PubMed ID: 23996108
[TBL] [Abstract][Full Text] [Related]
54. Optimizing the management of patients with myelofibrosis.
Manea PJ
Clin J Oncol Nurs; 2014 Jun; 18(3):330-7. PubMed ID: 24867113
[TBL] [Abstract][Full Text] [Related]
55. Janus activated kinase inhibition in myelofibrosis.
Malhotra H
Indian J Cancer; 2012; 49(3):260-5. PubMed ID: 23238141
[TBL] [Abstract][Full Text] [Related]
56. The new landscape of therapy for myelofibrosis.
Gowin K; Emanuel R; Geyer H; Mesa RA
Curr Hematol Malig Rep; 2013 Dec; 8(4):325-32. PubMed ID: 24101258
[TBL] [Abstract][Full Text] [Related]
57. Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.
Marchetti M; Barosi G; Cervantes F; Birgegård G; Griesshammer M; Harrison C; Hehlmann R; Kiladjian JJ; Kröger N; McMullin MF; Passamonti F; Vannucchi A; Barbui T
Leukemia; 2017 Apr; 31(4):882-888. PubMed ID: 27740634
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of ruxolitinib for myelofibrosis.
Santos FP; Verstovsek S
Expert Opin Pharmacother; 2014 Jul; 15(10):1465-73. PubMed ID: 24856675
[TBL] [Abstract][Full Text] [Related]
59. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
60. Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.
Yacoub A; Odenike O; Verstovsek S
Curr Hematol Malig Rep; 2014 Dec; 9(4):350-9. PubMed ID: 25145552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]